Epidermal Growth Factor (egf) Or Epidermal Growth Factor-like Or Derivative Patents (Class 514/9.6)
-
Publication number: 20140155326Abstract: Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.Type: ApplicationFiled: November 21, 2013Publication date: June 5, 2014Applicant: Janssen Biotech, Inc.Inventors: Anderson Mark, Ricardo Attar, Michael Diem, Linus Hyun, Steven Jacobs, Alastair King, Donna Klein, Sheri Moores, Karyn O'Neil, Kristen Picha
-
Patent number: 8741260Abstract: The invention provides compositions, methods, and kits for increasing transport of GDNF across the blood brain barrier while allowing its activity to remain substantially intact. The GDNF is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems.Type: GrantFiled: November 25, 2008Date of Patent: June 3, 2014Assignee: Armagen Technologies, Inc.Inventors: William M. Pardridge, Ruben J. Boado
-
Publication number: 20140121163Abstract: Methods of treating cerebral ischemia using milk fat globule epidermal growth factor-factor VIII (MFG-E8) are disclosed, as are recombinant human MFG-E8 and its uses in pharmaceutical compositions, products and methods for treating inflammation and organ injury after ischemia/reperfusion, sepsis, and lung injury.Type: ApplicationFiled: April 27, 2012Publication date: May 1, 2014Inventor: Ping Wang
-
Publication number: 20140121161Abstract: The invention provides hydrogels and methods for their use in treating disorders of the retina such as age-related macular degeneration (AMD).Type: ApplicationFiled: October 3, 2013Publication date: May 1, 2014Applicant: University of Louisville Research Foundation, Inc.Inventors: Andrea S. Gobin, Tongalp H. Tezel
-
Patent number: 8703917Abstract: Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration.Type: GrantFiled: January 26, 2011Date of Patent: April 22, 2014Assignee: Shanghai Cancer InstituteInventors: Zonghai Li, Hai Wang, Min Zhou, Xiaorong Pan, Jianren Gu, Shengli Yang
-
Publication number: 20140105824Abstract: Provided herein are diagnostic methods for identifying subjects susceptible to treatment with a hypoxia-activated agent, and related methods. Also provided herein are methods of monitoring treatments with anti-hyaluronan agents, and related methods.Type: ApplicationFiled: October 16, 2013Publication date: April 17, 2014Inventors: H. Michael Shepard, Xiaoming Li, Curtis Thompson
-
Publication number: 20140105990Abstract: The present invention is relevant to human medicine, and, in particular, to the use of Epidermal Growth Factor (EGF) in a pharmaceutical composition, said composition is administered through infiltration at the periphery of nerve trunks and/or ganglia, for the morphofunctional restoration of peripheral nerves in painful, sensitive-motor neuropathy, as well as ischemic neuritis. It is also relevant to an EGF containing composition, where this molecule can be formulated together with anesthetic or analgesic drugs, or encapsulated in microspheres, and their use for the morphofunctional restoration of peripheral nerves in painful, sensitive-motor neuropathy, as well as in ischemic neuritis.Type: ApplicationFiled: December 26, 2013Publication date: April 17, 2014Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Jose Ignacio Fernandez Montequin, Luis Saturnino Herrera Martinez, Jorge Amador Berlanga Acosta, Diana Garcia Del Barco Herrera, Danay Cibrian Vera, Gerardo Enrique Guillen Nieto, Raimundo Ubieta Gomez, Sonia Gonzalez Blanco, Vivian Maria Saez Martinez
-
Publication number: 20140105856Abstract: System and methods for isolation of collagen and other fibrous tissue from adipose tissue are described herein. The method of the present invention isolates the collagen from adipose tissue by sonication. The tissue to be sonicated is placed in a container or a flow cell transparent to ultrasound waves. After sonication the sonicated material is filtered out through the bottom of the flow cell and the sonicated collagen is trapped in the filter, which may be taken for further processing. The isolated collagen can then be combined with a suitable carrier for re-injection to correct various tissue defects such as wrinkles, to form a carrier for the stem cells, a filler, and matrix for new collagen production by injecting into the desired area of the host.Type: ApplicationFiled: June 22, 2012Publication date: April 17, 2014Inventor: Stephen Schendel
-
Publication number: 20140099270Abstract: The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.Type: ApplicationFiled: October 28, 2013Publication date: April 10, 2014Applicants: FORTUNEROCK, INC. USA, TIANJIN SINOBIOTECH LTD.Inventors: Yan Fu, Zailin Yu
-
Publication number: 20140094410Abstract: The present invention provides processes for producing porous silk fibroin scaffold material. The porous silk fibroin scaffold can be used for tissue engineering. The porosity of the silk fibroin scaffolds described herein can be adjusted as to mimic the gradient of densities found in natural tissue. Accordingly, methods for engineering of 3-dimensional tissue, e.g. bone and cartilage, using the silk fibroin scaffold material are also provided.Type: ApplicationFiled: November 19, 2012Publication date: April 3, 2014Inventors: David L. Kaplan, Rina Nazarov, Gordana Vunjak-Novakovic, Lorenz Meinel
-
Publication number: 20140086975Abstract: Formulations of cross-linkable polymers, capable of forming non-toxic and biocompatible hydrogels in situ, containing at least one of doxycycline or minocycline. Methods of using the hydrogels for treating the skin or ocular tissues of mammals exposed to vesicant compounds such as sulfur mustard (SM), nitrogen mustard (NM) or half mustard (2-chloroethyl ethyl sulfide (CEES)) are also disclosed.Type: ApplicationFiled: October 21, 2010Publication date: March 27, 2014Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Manjeet Deshmukh, SivaNaga S. Anumolu, Anupa Menjoge, Marion Gordon
-
Publication number: 20140088502Abstract: An injector system for delivery of a pharmacological agent to biological tissue having a plurality of needles arranged in an array, a plurality of reservoirs configured to receive a pharmacological composition therein, the reservoirs being in fluid communication with a respective one of the plurality of needles, a pneumatic pressure source, a pneumatic drive system that is configured to induce a first discharge of the pharmacological composition out of the reservoirs and needles in a plurality of delivery modes, agent delivery volume control means for controlling volume of the pharmacological composition discharged from the needles, and a control system having actuation control means for controlling said pneumatic drive system. The control system is programmed to control the delivery modes.Type: ApplicationFiled: September 19, 2013Publication date: March 27, 2014Inventors: Robert G. Matheny, Bret Herscher, Michael Perry
-
Publication number: 20140072531Abstract: A method for preparing polymer microparticles with a reduced initial burst, and the polymer microparticles prepared thereby, the method including: contacting polymer microparticles with an alcohol aqueous solution, the polymer microparticles prepared thereby, and use for drug delivery of the polymer microparticles.Type: ApplicationFiled: November 20, 2013Publication date: March 13, 2014Applicant: SK CHEMICALS CO., LTD.Inventors: Hong Kee KIM, Kyu Ho Lee, Joon-Gyo OH, Bong-Yong Lee
-
Publication number: 20140065119Abstract: Compositions and methods for treating wounds are provided. The compositions include cyclic analogues of histatin (5).Type: ApplicationFiled: November 10, 2011Publication date: March 6, 2014Applicant: THE UNIVERSITY OF WESTERN ONTARIOInventors: Gilles Andre Lajoie, Greg John Adams Vilk, Ian Welch
-
Patent number: 8658196Abstract: Described, in certain aspects of the invention, are multilaminate medical graft products, as well as methods for preparing and using the same. An illustrative multilaminate medical graft product of the invention comprises a first layer of remodelable extracellular matrix (ECM) material bonded to a second layer of remodelable ECM material, wherein the first material layer is enriched with a growth factor relative to the second material layer. Such a remodelable ECM material may be comprised of submucosa from a warm-blooded vertebrate, for example, porcine small intestinal submucosa (SIS).Type: GrantFiled: August 12, 2010Date of Patent: February 25, 2014Assignee: Cook Biotech IncorporatedInventor: Abram D. Janis
-
Publication number: 20140037593Abstract: The invention is directed to a composition comprising all or a portion of a beta-tricalcium phosphate (?-TCP) bound to all or a portion of a ?-TCP binding peptide and methods of use thereof.Type: ApplicationFiled: December 6, 2011Publication date: February 6, 2014Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Luis Alvarez, Linda G. Griffith, Yadir Guerrero, Linda Stockdale, Jaime Rivera
-
Publication number: 20130337076Abstract: The present invention concerns particles containing at least one covalently cross-linked polysaccharide and at least one growth factor, a method of preparation, and uses thereof.Type: ApplicationFiled: March 5, 2012Publication date: December 19, 2013Applicants: UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE, UNIVERSITE DE ROUENInventors: Ebba Brakenhielm, Sébastien Banquet, Florence Edwards-Levy, Christian Thuillez
-
Publication number: 20130331326Abstract: The present invention relates, in general, to hematopoietic reconstruction and, in particular, to a method of inducing hematopoietic reconstruction using EGF. The invention also relates to compounds and compositions suitable for use in such a method.Type: ApplicationFiled: February 21, 2012Publication date: December 12, 2013Applicant: DUKE UNIVERSITYInventor: John P. Chute
-
Patent number: 8603973Abstract: The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and freckles, and whitening skin. Particularly, the present invention provides various types of products for improving skin, which contain recombinant fusion protein of human serum albumin (HSA) with cytokine peptides (EGF, FGF, KGF, HGH, HGF, PDGF, GCSF, interferon, IL-11 or IGF) by genetic engineering technology. The fusion protein can be used independently or in a combination or combination with yeast fermentation products, or with varied emulsifiers, thickeners, moisturizer, preservatives, yeasts and ferments.Type: GrantFiled: September 24, 2008Date of Patent: December 10, 2013Assignees: Tianjin Sinobiotech Ltd., Fortunerock, Inc. USAInventors: Yan Fu, Zailin Yu
-
Publication number: 20130324466Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.Type: ApplicationFiled: May 29, 2013Publication date: December 5, 2013Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Thomas Parry
-
Publication number: 20130323199Abstract: A collagen material is characterized in being constituted of collagen gel fragments. Furthermore, the collagen gel fragments may have an orientation. A method for producing a collagen material is characterized in comprising a step for preparing collagen gel fragments, a step for arranging the collagen gel fragments in a desired shape, and a step for drying the collagen gel fragments arranged in the desired shape. Moreover, in one embodiment of the method for producing a collagen material a step may include imparting an orientation to the collagen gel fragments.Type: ApplicationFiled: February 20, 2012Publication date: December 5, 2013Applicant: Atree, Inc.Inventors: Taro Saku, Yoshihiro Isobe, Takaoki Isobe
-
Patent number: 8598113Abstract: This invention relates to polypeptides which bind to EGFR family receptors and to applications of those polypeptides in medicine, veterinary medicine, diagnosis diagnostics and imaging.Type: GrantFiled: July 16, 2012Date of Patent: December 3, 2013Assignee: Affibody ABInventors: Fredrik Nilsson, Tove Eriksson, Andreas Jonsson, Stefan Stahl, Mikaela Friedman
-
Publication number: 20130309304Abstract: The present invention relates to pharmaceutical formulations suitable for targeting particular tissue and/or organ(s) with a formulated active ingredient, for example when administered upstream of the target organ or tissue, and to use of the same in treatment, methods of treatment administering the same and methods of preparing the formulations. The pharmaceutical formulations of the invention are for parenteral administration to a target tissue and comprise particles containing an active ingredient, and a biodegradable excipient, wherein 90% or more of the particles have a diameter of between 10 and 20 microns and the formulation is substantially free of particles with a diameter greater than 50 microns and less than 5 microns, such that where the formulation is administered upstream of the target tissue the ability of the active to pass through the target tissue and pass into systemic circulation is restricted.Type: ApplicationFiled: March 15, 2013Publication date: November 21, 2013Inventor: Bernardo Nadal-Ginard
-
Publication number: 20130288965Abstract: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.Type: ApplicationFiled: March 14, 2013Publication date: October 31, 2013Inventors: JOHANNES GERHARDUS MARIA BOLSCHER, ARIE VAN NIEUW AMERONGEN, ENGELMUNDUS CORNELIS IGNATIUS VEERMAN, MENNO JOHANNES OUDHOFF, WILLEM VAN'T HOF, KAMRAN NAZMI, PETRONELLA ADRIANA MARIA VAN DEN KEIJBUS
-
Publication number: 20130288964Abstract: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.Type: ApplicationFiled: March 14, 2013Publication date: October 31, 2013Inventors: Johannes Gerhardus Maria Bolscher, Arie van Nieuw Amerongen, Engelmundus Cornelis Ignatius Veerman, Menno Johannes Oudhoff, Willem van't Hof, Kamran Nazmi, Petronella Adriana Maria van den Keijbus
-
Publication number: 20130288963Abstract: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an anti-angiogenic effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.Type: ApplicationFiled: January 5, 2012Publication date: October 31, 2013Applicant: ADAMED SP. Z O.O.Inventors: Jerzy Szczepan Pieczykolan, Sebastian Dominik Pawlak, Bartlomiej Maciej Zerek, Piotr Kamil Rózga
-
Patent number: 8568745Abstract: An object of the present invention is to provide a drug delivery carrier that is free from the drug leakage problem and has an easily controllable particle size, and that can be used to deliver water-soluble drugs such as genes and proteins in a wide range of applications, including delivery of water-soluble drugs that do not have high anionic properties, and also can be used as a non-viral gene vector. The invention also provides a process for production of such drug delivery carriers. The drug delivery carrier of the present invention includes a water-soluble drug double-coated with two types of inner and outer surfactants 1 and 2.Type: GrantFiled: June 16, 2010Date of Patent: October 29, 2013Assignee: Kyushu University, National University CorporationInventors: Masahiro Goto, Noriho Kamiya, Yoshiro Tahara
-
Publication number: 20130281372Abstract: The present invention relates to methods of reducing a level of a target mRNA in a well-differentiated airway epithelial cell by contacting the cell with a sensitizing agent followed by contacting the cell with a therapeutic RNAi agent.Type: ApplicationFiled: March 14, 2013Publication date: October 24, 2013Applicant: University of Iowa Research FoundationInventors: Paul B. McCray, JR., Beverly L. Davidson, Sateesh Krishnamurthy
-
Publication number: 20130272999Abstract: A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant.Type: ApplicationFiled: June 6, 2013Publication date: October 17, 2013Inventors: Krishna Murthy Ella, Srinivas Kannappa Vellimedu
-
Publication number: 20130266536Abstract: Cosmetic and dermatologic compositions for skin care, containing a transgenic plant extract containing a growth factor, or a growth factor purified from transgenic plants, or a mixture of growth factors derived from transgenic plants as extracts or in purified form, for use in topical therapeutics, dermatology and cosmetics. Importantly this invention provides stabilized, safer growth factors available for use for cosmetic and topical treatment. Preferred composition comprises a plant-produced growth factor and hyaluronic acid. The skin-care/dermatological compositions with stabilized growth factor do not carry the risk of unwanted breakdown products and the resulting loss of activity of the composition. Furthermore, the composition is without contaminants and transmissible agents that can result from animals or animal or bacterial cell based expression systems.Type: ApplicationFiled: January 6, 2011Publication date: October 10, 2013Inventor: Ágústa Guõmundsdóttir
-
Publication number: 20130251727Abstract: Observations regarding the role of MUC1 in promoting the nuclear accumulation of EGFR led us to propose the development of peptides to block nuclear accumulation of EGFR as a means to block breast cancer progression. One exemplary peptide, the ENLS1 peptide, promotes cell death in breast cancer cell lines. Studies in the MMTV-pyMT mouse model of breast cancer demonstrate significant anti-tumor activity.Type: ApplicationFiled: October 12, 2011Publication date: September 26, 2013Applicant: ARIZONA BIOMEDICAL RESEARCH COMMISSIONInventors: Joyce A. Schroeder, Benjamin G. Bitler, Aarthi Goverdhan
-
Publication number: 20130245528Abstract: Provided herein is a topical wound dressing that comprises a collagen and a flexible paste. Also provided is a wound dressing with a first layer of a sterilized mixture of collagen and a second adhesive layer effective to adhere to surrounding skin and to keep the first layer in contact with the wound. In addition there is provided a wound dressing foil that comprises collagen and a plastic compound that can provide a foil shape. Furthermore, methods of dressing wounds utilizing the wound dressings and wound dressing foil are provided herein.Type: ApplicationFiled: March 13, 2013Publication date: September 19, 2013Inventor: Carl Randall Harrell
-
Publication number: 20130243866Abstract: A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load therapeutic agents in active form for controlled release. The lipids are subsequently removed through the use of a dehydration agent, such as methanol or sodium chloride, resulting in ?-sheet structure dominant silk microsphere structures having about 2 ?m in diameter. The therapeutic agent can be entrapped in the silk microspheres and used in pharmaceutical formulations for controlled-release treatments.Type: ApplicationFiled: May 7, 2013Publication date: September 19, 2013Applicant: TRUSTEES OF TUFTS COLLEGEInventors: David L. KAPLAN, Xiaoqin WANG
-
Publication number: 20130244935Abstract: Methods of treating, abating and reducing the lisk for necrotizing enterocolitis (NEC) in an infant are disclosed. Preferred methods include admmistering an EGF receptor agonist, such as HB-EGF or EGF, within 24 hours following birth or following the onset of at least one symptom of NEC, in an amount effective to reduce the onset or seventy of NEC.Type: ApplicationFiled: March 11, 2013Publication date: September 19, 2013Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventor: Gail E. Besner
-
Patent number: 8530418Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: October 17, 2012Date of Patent: September 10, 2013Assignee: Stemnion, Inc.Inventors: Vivienne S Marshall, Catherine J Trumpower, Charlotte Emig
-
Publication number: 20130230598Abstract: A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 ?m.Type: ApplicationFiled: February 20, 2013Publication date: September 5, 2013Applicant: LG LIFE SCIENCES, LTD., INC.Inventors: Myung-Jin KIM, Sun-Jin KIM, Oh-Ryong KWON
-
Patent number: 8518879Abstract: The present invention relates to skin care compositions, including cosmeceuticals, for topical application, and more particularly, a skin cream, comprising cell culture medium conditioned by cells grown in two-dimensional culture. Also included are methods of using such compositions and kits comprising the skin cream therein.Type: GrantFiled: March 4, 2011Date of Patent: August 27, 2013Inventor: Ahmed H. Al-Qahtani
-
Publication number: 20130217624Abstract: A method of inhibiting postoperative adhesion severity of mammalian tissues. The method includes the application on an operated tissue surface of an effective therapeutic amount of a pharmaceutical composition containing a pharmaceutically acceptable amount of growth factors and sterilized carboxymethylchitosan. A method of inhibiting postoperative adhesion severity that includes the step of applying a composition comprising a growth factor, where the growth factor is used as a modulating factor on mesothelial cell proliferation is also provided.Type: ApplicationFiled: March 18, 2013Publication date: August 22, 2013Applicant: FUNDAÇÃO SÃO FRANCISCO XAVIERInventors: Fundação São Francisco Xavier, Jackson Brandão Lopes, Luis Alberto Oliveira Dallan
-
Publication number: 20130209368Abstract: The present invention provides particles comprising either a water-soluble polymer or a phospholipid, wherein at least one near infrared (NIR) fluorescent probe and optionally at least one active agent such as a targeting moiety, capable of selectively recognizing a particular cellular marker, are non-covalently bound to the outer surface of the particles.Type: ApplicationFiled: September 8, 2011Publication date: August 15, 2013Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTDInventors: Shlomo Magdassi, Philip Lazarovici, Liraz Larush, Emma Portnoy, Shimon Lecht, Ran Tivony
-
Publication number: 20130196911Abstract: The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue.Type: ApplicationFiled: March 24, 2011Publication date: August 1, 2013Applicants: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.Inventors: Steven M. Jay, Linda G. Griffith, Richard T. Lee
-
Publication number: 20130177614Abstract: Cosmetic and dermatologic compositions for skin care, containing a non-plant derived growth factor, purified from a host organisms or host cells such as bacterial, yeast, or animal cells, including insect cells, or a mixture of growth factors in purified form, for use in topical therapeutics, dermatology and cosmetics. Importantly this invention provides stabilized, safer growth factors available for use for cosmetic and topical treatment. Preferred composition comprises a non-plant derived growth factor and hyaluronic acid. The skin-care/dermatological compositions with stabilized growth factor do not carry the risk of unwanted breakdown products and the resulting loss of activity of the composition.Type: ApplicationFiled: July 6, 2012Publication date: July 11, 2013Inventors: Einar Mantyla, Bjorn Larus Orvar, Hakon Orn Birgisson
-
Publication number: 20130171094Abstract: This invention provides a method of promoting bone healing by locally administering a vanadium-based insulin mimetic agent to a patient in need thereof. The invention also provides a new use of insulin-mimetic vanadium compounds for manufacture of medicaments for accelerating bone-healing processes. In addition, the invention also encompasses a bone injury treatment kit suitable for localized administration of insulin-mimetic vanadium compounds or compositions thereof to a patient in need of such treatment.Type: ApplicationFiled: January 14, 2011Publication date: July 4, 2013Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Sheldon Suton Lin, David Naisby Paglia, James Patrick O'Connor, Eric Breitbart, Joseph Benevenia
-
Publication number: 20130172236Abstract: This invention provides methods for extracting platelets, compositions obtained therefore, and methods for using the same.Type: ApplicationFiled: October 5, 2012Publication date: July 4, 2013Applicant: The Regents of the University of Colorado, a body corporateInventor: Mark T. Roedersheimer
-
Publication number: 20130165376Abstract: The invention is related to methods of protecting, preventing and reducing intestinal injury in a human subject suffering from or at risk for shock, hemorrhagic shock or hemorrhagic shock and resuscitation (HS/R) comprising administering heparin binding epidermal growth factor (HB-EGF). The invention is also related to methods of inhibiting deterioration of intestinal blood flow and methods of preserving and increasing intestinal blood flow by administering HB-EGF to a human subject. In addition, the methods of the invention should improve the clinical outcome of human subject suffering from or at risk for shock, hemorrhagic shock or hemorrhagic shock and resuscitation.Type: ApplicationFiled: January 9, 2012Publication date: June 27, 2013Applicant: NATIONWIDE CHILDREN'S HOSPITAL INC.Inventors: Gail E. Besner, Osama N. El-Assal
-
Publication number: 20130156697Abstract: The invention in suitable embodiments is directed to an isolated protein comprising one or more amino acid sequences, each amino acid sequence capable of being functionalized and/or attached in whole and/or in part to one or more or a plurality of elements of one or more types including to cargo elements, forming a composition of elements suitable for use as an in vivo and/or in vitro medicament to treat one or more biological species.Type: ApplicationFiled: December 21, 2012Publication date: June 20, 2013Inventors: FRANCO VITALIANO, GORDANA DRAGAN VITALIANO
-
Patent number: 8466105Abstract: The present invention is drawn to methods of stimulating or enhancing angiogenesis in a patient comprising, administering to said patient a therapeutically effective amount of an endorepellin protein, wherein said endorepellin protein has an amino acid sequence of domain V of perlecan or fragments or derivatives, analogs thereof; and stimulating or enhancing generation of blood vessels. The present invention is drawn to compositions for enhancing angiogenesis.Type: GrantFiled: December 31, 2009Date of Patent: June 18, 2013Assignee: The Texas A&M University SystemInventor: Gregory J. Bix
-
Publication number: 20130150285Abstract: Therapeutic and cosmetic uses and applications of calreticulin are provided. In particular, the invention relates to therapeutic and cosmetic uses and applications of calreticulin to a patient in need of such treatment including in tissue repair, wound healing, ulcers, reducing scar formation, and reducing or eliminating wrinkles.Type: ApplicationFiled: June 17, 2011Publication date: June 13, 2013Applicants: CALREGEN INC., NEW YORK UNIVERSITYInventors: Leslie I. Gold, Marek Michalak
-
Patent number: 8452483Abstract: A cell-based vehicle driving control system includes a local server for obtaining road environment information on roads within a cell and target vehicle information on a target vehicle within the cell and generating local waypoints based on the road environment information and the target vehicle information; a global server for monitoring the target vehicle information, the road environment information and local server information on the local server received from the local server; and a vehicle control terminal, mounted in the target vehicle, for receiving the local waypoints from the local server and controlling the target vehicle based on the local waypoints. The road environment information is obtained by using at least one sensor installed on the roads.Type: GrantFiled: June 21, 2010Date of Patent: May 28, 2013Assignee: Electronics and Telecommunications Research InstituteInventors: Do Hyun Kim, Sung Won Sohn, Jong-Hyun Park, Byung Tae Jang, Jeong Dan Choi, Kyung Bok Sung, Kyoung Hwan An, Ju Wan Kim, Seong Ik Cho, Jungsook Kim
-
Publication number: 20130130984Abstract: The invention provides for methods of protecting neurons within the enteric nervous system (ENS) comprising administering an EGF receptor agonist, such as heparin-binding EGF (HB-EGF). These methods include reducing damage of ENS neurons in patient s suffering from an intestinal injury. In addition, the invention provides for increasing intestinal motility in a patient suffering from an intestinal injury comprising administering HB-EGF. The invention also provides for methods of inducing neurite growth within the ENS in a patient suffering from intestinal injury comprising administering HB-EGF.Type: ApplicationFiled: November 6, 2012Publication date: May 23, 2013Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventor: Nationwide Children's Hospital, Inc.
-
Publication number: 20130115302Abstract: A polysaccharide micro-particle encapsulating a growth factor is disclosed and shall include one or more growth factors, and a polysaccharide shell forming a space to encapsulate the growth factor by electrostatic interaction. Also, a method for manufacturing a polysaccharide micro-particle encapsulating a growth factor is disclosed, which shall include the following process: (A) providing a pH 4.6-6 polysaccharide solution and a growth factor; and (B) adding the growth factor to the polysaccharide solution, and adjusting the polysaccharide solution to a pH of 6-8 to obtain the polysaccharide micro-particle encapsulating the growth factor by electrostatic interaction. According to the polysaccharide shell structure, the growth factor can be stored for a long period of time and heal skin wounds, mucositis, and corneal ulcer effectively.Type: ApplicationFiled: April 4, 2012Publication date: May 9, 2013Applicant: MICORNA DERMAL THERAPY LAB CO., LTD.Inventor: Le Shin CHANG